The role of Irisin in modulating hypoxia-related disorders: New insights and implications for cancer therapy

Abstract

Regular physical activity is well-known for its health benefits, including reducing the risk of chronic diseases like cancer. Irisin, a myokine released by skeletal muscles during exercise, has emerged as a key regulator in hypoxiarelated disorders.Hypoxia, defined by reduced oxygen availability, is a hallmark of various pathological conditions, especially cancer, where it drives tumor growth, metastasis, and resistance to therapy. Recent studies suggest that irisin can modulate hypoxia-induced pathways, impacting processes such as angiogenesis, inflammation, and metabolic adaptation. By targeting these mechanisms, irisin may enhance the efficacy of cancer treatments, reduce tumor aggressiveness, and potentially overcome therapy resistance. Additionally, irisin’s influence on the tumor microenvironment highlights its potential as a therapeutic agent to counteract hypoxiadriven cancer progression. This review summarizes current findings on irisin’s role in hypoxia-related disorders, focusing on its molecular mechanisms and potential applications in oncology. Despite promising preclinical studies, further research is necessary to fully understand irisin’s therapeutic potential, optimize delivery methods, and validate its safety and efficacy in clinical settings. Exploiting exercise-derived molecules such as irisin may enable novel strategies for cancer treatment and other hypoxia-related diseases